Todas las noticias

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that the Board of Directors of Spineway (the “Company”) decided at its meeting of December 4, 2024, acting on a delegation of authority granted by the Combined General Meeting of March 25, 2024, under the terms of its twenty-third resolution, to carry out a capital reduction motivated by losses through a reduction in the par value of its shares.

The Spineway Group, a , specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international surgeons in the use of the Group’s ESP cervical and lumbar prostheses. These events also enabled the Group's distributors to provide ongoing training and support for their users.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, took part in the EUROSPINE 2024 Congress, Europe’s leading spine conference, held from October 2 to 4, in Vienna, Austria. During the event, which brought together more than 3,500 spine surgeons and professionals from all over the world, Spineway enjoyed a prime location in the heart of the Messe Wien congress center, making its stand a must see for all congress attendees.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, recorded an excellent third quarter in 2024, with revenue of €2.6 million, representing purely organic growth (excluding change in the scope of consolidation) of 24% compared with the previous year. As a result, ninemonth revenue was €9.1 million, an increase of 21% on 2023.

Spineway, a specialist in innovative implants for the treatment of severe spinal pathologies, continues its organic growth (without scope effect) and achieves a turnover of €6.5 million for the first half of 2024, up 20% compared to S1 2023. The gross margin remains at a normative level of 69%, stable compared to the end of 2023 and in line with the Group's forecasts.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 24th AMCICO (Asociación Mexicana de Cirujanos de Columna) congress in Cancún from September 4 to 8, 2024. This annual congress of spine surgeons is a flagship event for the spine surgery sector in Mexico, the largest market in Central and Latin America.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is taking part in the Sociedad Iberolatinoamericana de Columna (SILACO) Congress in Mexico from July 24 to 27, 2024 with two local partners, Spinemed and Mava. As a Gold Sponsor of this major event in Latin America, Spineway will increase its visibility among spine surgeons and professionals in this strategic region.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, continued its entirely organic growth (no change in scope) in the second quarter of 2024, recording revenue of €3.4 million. This good performance brings half-year revenue to €6.5 million, representing growth of 20% compared with H1 2023. As a reminder, organic growth was 12% in H1 2023,1 reflecting the Group’s positive trajectory.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, organized a hands-on training workshop entitled “Hands-on Total Disc Replacement featuring ESP technology” at the Institut de Recherche contre les Cancers de l’Appareil Digestif (IRCAD) in Strasbourg on June 28, 2024. During the event, Spineway’s ESP prostheses (cervical and lumbar) were presented to 25 surgeons and professionals, with a presentation of the products, their indications and two surgical approach sessions.